Digestery
Longevity supplements › NMN and Aging › Studies

Randomized trial · measured other health measures

A 4-week NMN trial in 30 adults: lower weight and cholesterol, no strength change

Pencina and colleagues · The Journal of clinical endocrinology and metabolism · 2023

Original title: Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Mixed

Body weight fell (difference -1.9 [-3.3, -0.5] kg, P = .008) and LDL cholesterol fell (-18.73 [-31.85, -5.60] mg/dL). Muscle strength, fatigue, aerobic capacity, stair power and insulin sensitivity did not differ.

The study at a glance

Type of study
Randomized trial
Who or what was studied
30 people · Overweight or obese adults aged 45 and over
What was tested
Two 500 mg tablets of NMN (MIB-626) twice a day for 28 days, vs placebo
What it measured
Several kinds of outcomes
Daily amount
2000 mg a day
How long
4 weeks
Who has a stake
Company stake
Funded in part by Metro International Biotech, which makes the MIB-626 tested; no COI statement in PubMed.
Journal
The Journal of clinical endocrinology and metabolism, 2023
Source
PubMed record 36740954. This page is based on the abstract only.

How much this study counts

  • ✓Randomized: people were put into groups by chance, so the groups start out alike.
  • ✓Compared with a placebo, a dummy treatment.
  • –Small: 30 people. Small trials can miss real effects or find chance ones.
  • –Short: 4 weeks. Longer-term effects are unknown.
  • •Measured several kinds of outcomes.
  • –Company stake: Funded in part by Metro International Biotech, which makes the MIB-626 tested; no COI statement in PubMed.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: aging and age-related decline

    0

    Not done yet. This is the step that would answer the question.

  2. Trials in people: other measures

    9

    3 benefit, 2 mixed, 4 no difference

    ↑ This study is the ringed dot

  3. Trials in people: lab tests or safety

    7

    4 benefit, 1 mixed, 2 no difference

  4. Population studies

    0

    None among the papers we read.

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    6

    5 benefit, 1 mixed

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does NMN slow aging?”

Not shown in people so far.

Confidence: very low. Based on 29 on-topic papers.

Read the full answer

Of the other 8 papers on the same step: 3 benefit, 1 mixed, 4 no difference. This one found mixed.

Other papers on the same step

See all 29 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The reviewer corrected 3 fields after reading the abstract. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.